Dow Jumps 150 Points; Ocean Bio-Chem Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday.
U.S. Stocks Turn Higher; Athira Pharma Shares Plummet
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 30 points on Wednesday.
40 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma’s Alzheimer’s Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours:
Why Athira Pharma Stock Is Plunging
Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease.
Athira Pharma Shares Fall To 52-Week Low – Read Why
Athira Pharma Inc (NASDAQ:ATHA) shares are falling to 52-week lows after announcing disappointing topline results from its exploratory ACT-AD Phase 2…
Athira Pharma Announces Topline Results From ACT-AD Phase 2 Proof Of Concept Study Of Fosgonimeton In Mild-to-Moderate Alzheimer’s Disease; Primary Endpoint Of Change In Biomarker ERP P300 Latency Was Not Statistically Significant
Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together showed potential
Athira Pharma Q1 EPS $(0.56) Down From $(0.25) YoY
Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.56) per share. This is a 124 percent decrease over losses of $(0.25) per share from the same period last year.
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.